-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Category Archives: Ophthalmology
Mobius brand Mitosol Recall
Mobius brand Mitosol (mitomycin for solution) Kit for Ophthalmic Use: Recall-May Not be Sterile AUDIENCE: Ophthalmology ISSUE: Mobius Therapeutics announced that it is conducting a voluntary recall of 2 lots of Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic … Continue reading
Posted in FDA 2013, FDA Recall, Ophthalmology
Tagged brand, drug risks, FDA recall, Mitosol, Mobius, Mobius brand Mitosol Recall, Mobius Therapeutics, Ophthalmology, Recall
Comments Off
Franck’s Lab Brilliant Blue Recall
Franck’s Compounding Pharmacy Sterile Preparations: Reports of Fungal Endophthalmitis, Expanded Recall 5/24/2012 AUDIENCE: Ophthalmology, Urology, Primary Care, Pharmacy ISSUE: FDA is notifying all physicians and medical care organizations who have ordered any compounded product sold as a sterile preparation by … Continue reading
Posted in FDA 2012, FDA Recall, Ophthalmology, Risk Manager
Tagged drug risks, FDA recall, FDA warning, Franck’s Lab Brilliant Blue Recall, Recall, Risk Manager
Comments Off
Brilliant Blue G Recall
Brilliant Blue G: Recall of Unapproved Drug – Ongoing Investigation of Fungal Endophthalmitis Cases AUDIENCE: Ophthalmology, Risk Manager ISSUE: FDA has received reports of fungal endophthalmitis (eye infections) in patients who were given Brilliant Blue G (BBG) during eye surgeries. Clinicians … Continue reading
Posted in FDA 2012, FDA Recall, Ophthalmology, Risk Manager
Tagged Brilliant Blue G Recall, drug risks, eye infections, eye surgery, FDA recall, Franck’s Compounding Lab, fungal endophthalmitis, Fungal Endophthalmitis Cases, Ocala Florida, Ongoing Investigation, Ophthalmology, Recall, Unapproved Drug
Comments Off